Research peptides in 2027: what changed in 2025–2026 and what to check before you order

Published November 2, 2026. This guide records what changed in the U.S. research-peptide market during 2025 and 2026, with a date and a source for each event, then sets out what to check before ordering in 2027. It makes no prediction about 2027 itself; where a regulator's process is still open, it says so and stops.

What changed in 2025–2026: a dated timeline#

Three things moved at once: the compounding status of several well-known peptides changed twice, two of the largest research-use-only vendors stopped selling, and public third-party test listings became large enough to check a vendor against. Each row cites a source opened while writing this page.

The compounding changes, and what they do not change#

The FDA list that matters here is the interim list of bulk drug substances nominated for use in compounding under section 503A of the Food, Drug, and Cosmetic Act. Category 1 holds nominated substances under evaluation; category 2 holds substances FDA said raise significant safety concerns; category 3 holds nominations filed without adequate support.^[8] In September 2023 FDA moved a group of peptides into category 2, citing concerns such as immunogenicity and peptide-related impurities; reports put the group at 17 or 19 substances depending on how salts and free bases were counted.^[1][2]

The reversal came in two steps. In September 2024, five peptides left category 2 after their nominators withdrew the nominations; for the October 29, 2024 advisory meeting FDA recommended that none be added to the bulks list.^[3] On April 15, 2026, twelve more left category 2 on the same procedural basis.^[5][6] Removal from category 2 is not a placement in category 1 and is not permission to compound; Polsinelli wrote that "that procedural removal should not be read as a go-ahead to compound these peptides."^[2]

In July 2026 the committee recommended six of seven for the bulks list over FDA staff objections. Two outlets agree on BPC-157, KPV and TB-500 at 8 in favor and 6 against, and MOTS-c at 7 to 5.^[11][12] Regulatory Focus reported Semax 8 to 5, epitalon 7 to 5 with one abstention, and emideltide rejected 6 to 7 with one abstention.^[12] A committee vote is a recommendation. As AJMC put it, "legal compounding remains prohibited absent FDA acceptance and completion of proposed and final rulemaking."^[11]

The October 28, 2026 HHS policy is the newest step and the most often misread. It is an interim statement that HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound the six peptides when all ten conditions are met, among them that the bulk substance come from an FDA-registered facility with a certificate of analysis covering identity, purity, potency and contaminants, that the manufacturer's location appear on that certificate, and that the product be labelled "This is a compounded drug product. Not for resale."^[19][20] The policy says it is meant to "discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers."^[19][21] Nothing in it covers research-use-only vendors or changes the status of a research-use-only vial. It formalizes the distinction: a compounded drug is a pharmacy product dispensed on a prescription; a research reagent is not.

The warning letters, and why "research use only" was not enough#

On August 24, 2026, FDA's Center for Drug Evaluation and Research sent warning letters to five online vendors selling peptides labelled for research use.^[13][14][15] Each letter alleged that the products were unapproved new drugs. The reasoning is the part a buyer should read. In a footnote repeated across the letters, FDA wrote that "despite statements on your product labeling marketing your products for 'research use only' ... evidence obtained from your website establishes that your products are intended to be drugs for human use."^[13] The evidence it pointed to was the website around the label: disease claims on product pages, calculators and instructions for preparing the material for administration, and bacteriostatic water sold alongside peptides as a set.^[14][15]

Two things follow. A research-use-only label is a statement about intended use, and FDA reads intended use from the whole site. And a vendor whose pages tell you how to use a compound on yourself has, in FDA's words, established the opposite of what its label says. A buyer can read a supplier's pages the same way FDA does.

Two closures, and the pattern that followed each#

Peptide Sciences' notice went up at about 2:00 p.m. Eastern on March 6, 2026, according to the first detailed report; the company gave no reason.^[4] Our page on the notice records its current wording and the company's warning that it has authorized no successor. Soma Chems ran a 60 percent close-out sale ending October 12, 2026, and by mid-October its pages carried one sentence: "Our store is no longer accepting new orders."^[17][18] Its terms stated that all sales were final; our vendor-closure guide records what the site showed and what recourse its terms left.

What followed each closure is the reason this page exists. Within days, "alternatives to" pages appeared, most built around affiliate codes; within weeks, domains and press releases using the closed vendor's name appeared, some describing themselves as separate businesses and some not. Treat every successor claim as unverified until the closed vendor's own domain confirms it; Peptide Sciences' notice says the same.^[4] Our vendor-closure guide lists the closures we could date and the 72-hour pattern.

Public test listings became large enough to use#

Until recently, the only test record for a research-peptide vial was the certificate the vendor chose to publish. Finnrick accepts sealed vials from the public (U.S. shipments only, batch number required), relabels them so the laboratory does not know the vendor, commissions testing from commercial laboratories with no ties to the vendor, and publishes the findings; its May 2026 account reported more than 10,000 tests, most on crowdsourced samples, and described catching a laboratory calibration error by comparing five certificates from one batch.^[9][10] It also runs a page for checking whether a certificate attributed to one of its tests is genuine.^[9] Separately, Janoshik Analytical, a Prague laboratory many vendors use for HPLC purity and LC-MS identity work, issues reports with a QR code that resolves on its public verification site.^[22]

A vendor's own certificate can now be compared with an outside record. Where a product has a public listing, it shows whether the vial that reached a customer matched the vendor's certificate. Where it has none, the certificate stands alone and has to be checked as our guide to verifying a certificate of analysis is genuine describes.

What to check in 2027#

Each item below is something you can verify on a vendor's site or on a document in your hand, and each follows from an event above. Run the list on every supplier you consider, including Renuvia Labs.

1. A U.S. legal entity, city and address, published on the site. The HHS policy's requirement that a manufacturer's location appear on a certificate is a pharmacy rule, but the principle is general: if you cannot find out who you are paying, you cannot pursue them.^[19] Look in the footer, the terms and the privacy policy.
2. A lot number on the label. Every vial should carry a lot or batch number, and it should match the certificate. Finnrick will not accept a public sample without a batch number for the same reason: without one, no test can be tied to the vial.^[9] Our batch-traceability page explains what a lot number should let you trace.
3. One certificate per lot, naming the laboratory. A single certificate shown for every size and restock of a product is a copy, not a record. The laboratory's name should be findable independently of the certificate, and where the laboratory offers a lookup (a QR code, a report number page), use it.^[22]
4. Purity and net peptide content as separate figures. An HPLC purity percentage says what fraction of the detected material is the main peak; it does not say how much peptide is in the vial or confirm identity, which takes mass spectrometry. Look for purity, identity and measured content as three fields with three methods. Our pages on purity-report misreadings and reading a certificate of analysis walk through each.
5. Supplier-provided or independent certificate, stated plainly. A synthesis manufacturer's certificate for a bulk batch is evidence about the raw material, not the finished vial. A vendor should say which kind it is showing; Renuvia labels supplier-provided certificates as such in its COA library.
6. Research-use-only labelling that the rest of the site supports. After the August 2026 warning letters, read the vendor's pages the way FDA did: product pages that make disease claims, give amounts, or bundle preparation tools with the product have told you how the vendor regards its own label.^[13][14] A supplier of research reagents should require an acknowledgement of research use at checkout and should have nothing on its pages that contradicts it.
7. Shipping only within the United States. Cross-border shipments of unapproved substances are a customs question in both directions, and the HHS policy singles out research-use-only peptides from foreign manufacturers as what it means to displace.^[19] A domestic-only U.S. vendor has a shorter chain of custody and is answerable to U.S. law.
8. A published refund or replacement policy that does not depend on how you paid. "All sales are final" plus a no-recourse payment method leaves nothing if a shipment never arrives or a vendor closes with orders open.^[18] Card payments can be disputed; person-to-person transfers, gift cards and cryptocurrency generally cannot. Stripe's list shows the categories a mainstream processor will not carry; a vendor with no card option has usually been told why.^[16]

Where Renuvia Labs stands against the list#

Renuvia Labs is a research-peptide supplier in Dallas, Texas, selling for laboratory research use only and shipping within the United States. Lots are tested by Freedom Diagnostics Testing for HPLC-UV purity, LC-MS identity and measured content, and each lot's report is listed in the COA library; some products carry supplier-provided certificates, labelled as such; lots whose report has not been issued show as pending. We have no affiliation with Peptide Sciences, Soma Chems or any other closed vendor and honor none of their codes. Run the eight checks above on us as you would on anyone else; our supplier-vetting guide sets out how. This page does not predict what FDA or HHS will do next and does not rank vendors; if a date above is wrong, email support@renuviaus.com with the source and it will be corrected.